Your browser doesn't support javascript.
loading
ω3 fatty acid metabolite, 12-hydroxyeicosapentaenoic acid, alleviates contact hypersensitivity by downregulation of CXCL1 and CXCL2 gene expression in keratinocytes via retinoid X receptor α.
Saika, Azusa; Nagatake, Takahiro; Hirata, So-Ichiro; Sawane, Kento; Adachi, Jun; Abe, Yuichi; Isoyama, Junko; Morimoto, Sakiko; Node, Eri; Tiwari, Prabha; Hosomi, Koji; Matsunaga, Ayu; Honda, Tetsuya; Tomonaga, Takeshi; Arita, Makoto; Kabashima, Kenji; Kunisawa, Jun.
Afiliação
  • Saika A; Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.
  • Nagatake T; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
  • Hirata SI; Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.
  • Sawane K; Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.
  • Adachi J; Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.
  • Abe Y; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
  • Isoyama J; Nippon Flour Mills Co., Ltd, Innovation Center, Atsugi, Japan.
  • Morimoto S; Laboratory of Proteome Research and Laboratory of Proteomics for Drug Discovery, NIBIOHN, Osaka, Japan.
  • Node E; Laboratory of Proteome Research and Laboratory of Proteomics for Drug Discovery, NIBIOHN, Osaka, Japan.
  • Tiwari P; Division of Molecular Diagnosis, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Hosomi K; Laboratory of Proteome Research and Laboratory of Proteomics for Drug Discovery, NIBIOHN, Osaka, Japan.
  • Matsunaga A; Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.
  • Honda T; Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.
  • Tomonaga T; Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.
  • Arita M; Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.
  • Kabashima K; Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.
  • Kunisawa J; Department of Food and Life Science, School of Life and Environmental Science, Azabu University, Sagamihara, Japan.
FASEB J ; 35(4): e21354, 2021 04.
Article em En | MEDLINE | ID: mdl-33749892

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Queratinócitos / Ácido Eicosapentaenoico / Dermatite de Contato / Quimiocina CXCL1 Idioma: En Revista: FASEB J Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Queratinócitos / Ácido Eicosapentaenoico / Dermatite de Contato / Quimiocina CXCL1 Idioma: En Revista: FASEB J Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão